According to reports, the proposed Debt limit budget may put pressure on the budget of the US Food and Drug Administration.


Steven Grossman, the director of the stronger FDA alliance, stated that the legislation's non defense federal funding cap makes it more difficult to increase funding for projects such as the FDA budget, and may pose a threat to existing funding for some agencies. For institutions whose missions and responsibilities are constantly expanding every year, this has never been a good situation, just like the situation with the FDA, "he wrote.


The 2023 Financial Responsibility Act limits non defense federal spending to $704 billion for the next two years. According to Grossman, after excluding medical and funding adjustments for veterans' affairs, the remaining non defense funds are approximately $637 billion, which is basically the same as in the 2023 fiscal year.


Although FDA's funds are limited by the macro budget level determined by the Debt limit, there is still room to determine the amount of funds that can be specifically allocated to FDA.


The mission and responsibility of the FDA are very important and obvious, "he wrote. It requires resources to protect public health and safety, and to set standards for products that account for 20% of all consumer spending (approximately $2.7 trillion)


Last month, the House Republican Appropriation bill of FDA approved the appropriation of the FDA Agriculture Subcommittee; It will provide a total funding of $6.6 billion and a fixed discretionary funding of $3.5 billion.